Instead, classification was based on relatedness to RET positive families by pedigree comparison along with MEN2 features other than MTC and the presence of MEN2 family history in the vast majority of molecularly unclassified patients (Table 2). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.